Publications by authors named "Miguel Corbellas"
Retrospective multicenter study of elderly patients with platinum-sensitive relapsed ovarian cancer treated with trabectedin and pegylated liposomal doxorubicin (pld) in a real-world setting: a geico study.
María Jesús Rubio Aránzazu Manzano Luis Miguel de Sande Purificación Estévez-García María Del Mar Gordon Miguel Corbellas
BMC Cancer
July 2024
Article Synopsis
- A study looked at how well a medicine called trabectedin, combined with another medicine called PLD, works for older patients with ovarian cancer that came back after treatment.
- The study involved 43 patients who were at least 70 years old, and it found that some responded well to the treatment, with 9.3% having a complete response and 32.6% showing partial improvement.
- The results suggest that this treatment is both effective and safe for older patients, which is important for helping them feel better during their care.
Context: The combination of gemcitabine and erlotinib is a standard first-line treatment for unresectable, locally advanced or metastatic pancreatic cancer. We reviewed our single centre experience to assess its efficacy and toxicity in clinical practice.
Methods: Clinical records of patients with unresectable, locally advanced or metastatic pancreatic cancer who were treated with the combination of gemcitabine and erlotinib were reviewed.